Advance in linezolid-induced thrombocytopenia

doi:10.12092/j.issn.1009-2501.2018.10.017

Abstract

Abstract:

Linezolid (LZD) has good antibacterial activity against methicillin-resistant staphylococcus aureus,penicillin-resistant pneumococcus and vancomycin-resistant enterococci. However, platelet toxicity greatly limits its clinical application. In recent years,significant progress has been acheived in studies of the pathogenesis and clinical risk factors of linezolid-induced thrombocytopenia（LIT）. LZD has been found to be closely related to bone marrow suppression, inhibition of platelet release,oxidative stress and immune destruction to result in low platelet count.In addition,a large number of clinical studies had also summarized the risk factors of LIT,and explored the dose adjustment methods of LZD,which became the breakthrough of prevention and treatment for LIT.However,there are many different kinds of opinoins in these literatures.This article reviews the pathogenesis,risk factors,and dose adjustment of LIT,with a view to providing ideas for clinical prevention and treatment of LIT.

Key words: linezolid, thrombocytopenia, risk factors, dose adjustment

CLC Number:

R558+.2

ZHONG Ling, SHAO Hua, CHEN Yan, HU Linlin, YU Feng. Advance in linezolid-induced thrombocytopenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1196-1200.

References

［1］Dryden MS.Linezolid pharmacokinetics and pharmacodynamics in clinical treatment［J］.J Antimicrob Chemother,2011,66 Suppl 4(Supplement 4):iv7-iv15.
［2］Yuasa A, Sato S, Houzawa H, et al. Postmarketing surveillance of linezolid［J］. Jpn J Chemother, 2017, 65(3): 491-509.
［3］Rabon AD,Fisher JP,MacVane SH,et al.Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater［J］.Ann Pharmacother,2018 Jun 1:1060028018783498.
［4］王东晓，朱曼，郭代红，等. 930例糖肽类和噁唑烷酮类抗感染药物药品不良反应/事件报告分析［J］. 中国药物应用与监测, 2017, 14(1): 37-41.
［5］徐佳，黄琪，杨志玲. 我院区2016年利奈唑胺临床应用合理性评价［J］. 中国临床药理学与治疗学, 2018, 23(1): 110-115.
［6］Li Y, Xu W. Efficacy and safety of linezolid compared with other treatments for skin and soft tissue infections: a meta-analysis ［J］. Biosci Rep, 2018, 38(1): BSR20171125.
［7］Gonzálezdel CJ, Candel FJ, Manzanolorenzo R, et al. Predictive score of haematological toxicity in patients treated with linezolid ［J］. Eur J Clin Microbiol Infect Dis, 2017, 36(8): 1511-1517.
［8］Silva ED, Kim H. Drug-induced thrombocytopenia: Focus on platelet apoptosis ［J］. Chem Biol Interact, 2018, 284: 1-11.
［9］Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients［J］. Antimicrob Agents Chemother, 2011, 55(5): 1867-1873.
［10］Bernstein WB, Trotta RF, Rector JT, et al. Mechanisms for linezolid-induced anemia and thrombocytopenia ［J］. Ann Pharmacother, 2003, 37(4): 517-520.
［11］Pascoalinho D, Vilas MJ, Coelho L, et al. Linezolid-related immune-mediated severe thrombocytopenia［J］. Int J Antimicrob Agents, 2011, 37(1): 88-89.
［12］Chong BH, Chong JH. Drug-induced thrombocytopenia: pathogenesis, diagnosis and management［M］// Platelets in thrombotic and non-thrombotic disorders. Springer International Publishing, 2017:153.
［13］Deng J, Su LX, Liang ZX, et al. Effects of vitamin b6 therapy for sepsis patients with linezolid-associated cytopenias: a retrospective study ［J］. Curr Ther Res Clin Exp, 2013, 74: 26-32.
［14］Flanagan S, Mckee EE, Das D, et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function［J］. Antimicrob Agents Chemother, 2015, 59(1): 178-185.
［15］Milosevic TV, Payen VL, Sonveaux P, et al. Mitochondrial alterations (inhibition of mitochondrial protein expression, oxidative metabolism and ultrastructure) induced by linezolid and tedizolid at clinically-relevant concentrations in cultured human HL-60 promyelocytes and THP-1 monocytes［J］. Antimicrob Agents Chemother, 2018, 62(3): pii: e01599-17.
［16］Nishijo N, Tsuji Y, Matsunaga K, et al. Mechanism underlying linezolid-induced thrombocytopenia in a chronic kidney failure mouse model［J］. J Pharmacol Pharmacother, 2017, 8(1): 8-13.
［17］Tajima M,Kato Y,Matsumoto J,et al.Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2［J］.Biol Pharm Bull,2016,39(11):1846-1851.
［18］Aburima A, Walladbegi K, Wake JD, et al. cGMP signaling inhibits platelet shape change through regulation of the RhoA‐Rho Kinase‐MLC phosphatase signaling pathway［J］. J Thromb Haemost, 2017, 15(8): 1668-1678.
［19］Wang TL, Guo DH, Bai Y, et al. Thrombocytopenia in patients receiving prolonged linezolid may be caused by oxidative stress ［J］. Clin Drug Investig, 2016, 36(1): 67-75.
［20］Araujo CF, Lacerda MV, Abdalla DS, et al. The role of platelet and plasma markers of antioxidant status and oxidative stress in thrombocytopenia among patients with vivax malaria［J］. Mem Inst Oswaldo Cruz, 2008, 103(6): 517-521.
［21］Wang T, Guo D, Dong X, et al. Effect of linezolid on hematological and oxidative parameters in rats ［J］. J Antibiot, 2014, 67(6): 433-437.
［22］Tsuji Y,Holford NHG,Kasai H,et al.Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients［J］.Br J Clin Pharmacol,2017,83(8):1758-1772.
［23］Aster RH, Bougie DW. Drug-induced immune thrombocytopenia ［J］. Am J Hematol, 2015, 68(1): 1-2.
［24］Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience［J］. Antimicrob Agents Chemother, 2002, 46(8): 2723-2726.
［25］Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program ［J］. Clin Infect Dis, 2003, 36(2): 159-168.
［26］Ballesteros MG, Orós MM, Díaz EV, et al. Myelosupression induced by linezolid: a pediatric case［J］. Arch Argent Pediatr, 2017, 115(6): e420-e423.
［27］Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy［J］. J Infect Chemother, 2011, 17(3): 382-387.
［28］Rabon A, Fisher J, Mazur J, et al. Incidence and risk factors for linezolid-associated thrombocytopenia in critically ill patients ［J］. Critical Care Medicine, 2018, 46: 319.
［29］Wu HJ, Wen CH, Jang YT, et al. DI-056 Linezolid induced thrombocytopenia in a patient with renal insufficiency: A case report and a retrospective case study［J］. Eur J Hosp Pharm Sci Pract. 2016, 23(Suppl 1): A142.2-A143.
［30］Hanai Y, Matsuo K, Ogawa M, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia ［J］. J Infect Chemother, 2016, 22(8): 536-542.
［31］Niwa T, Watanabe T, Suzuki A, et al. Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight［J］. Diagn Microbiol Infect Dis, 2014, 79(1): 93-97.
［32］Jia LI, Fan YH, Liao LW, et al. Risk factors for linezolid-associated thrombocytopenia in critically ill adult patients［J］. Chin J Hosp Pharm, 2016.
［33］Niwa T, Suzuki A, Sakakibara S, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy ［J］. Clin Ther, 2009, 31(10): 2126-2133.
［34］Ikuta S, Tanimura K, Yasui C, et al. Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus -infected patients after digestive surgery［J］. J Infect Chemother, 2011, 17(3): 388-391.
［35］Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients［J］. Int J Antimicrob Agents, 2014, 44(3): 242-247.
［36］Ichie T, Suzuki D, Yasui K, et al. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis ［J］. J Clin Pharm Ther, 2015, 40(3): 279-284.
［37］Zhang YM, Yu W, Zhou N, et al. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid ［J］. Hepatobiliary Pancreat Dis Int, 2015, 14(3): 287-292.
［38］Hiraki Y, Tsuji Y, Hiraike M, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia［J］. Scand J Infect Dis, 2012, 44(1):60-64.
［39］Pea F, Cojutti P, Pagotto A, et al. Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy ［J］. Antimicrob Agents Chemother, 2012, 56(6): 3438-3440.
［40］Kato H, Mao H, Yamagishi Y, et al. Is dose adjustment based on several factors of body size descriptors effective for prevention of thrombocytopenia by linezolid therapy in hemodialysis patients ［J］? Pharmacol Pharm, 2016, 7(10):417-423.
［41］Cojutti P, Pai MP, Pea F. Population pharmacokinetics and dosing considerations for the use of linezolid in overweight and obese adult patients［J］. Clin Pharmacokinet, 2018, 57(8): 989-1000.
［42］Taguchi K,Miyakawa T,Ohmura T,et al.A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency［J］.Scand J Infect Dis,2013,45(1):77-80.

[1]	YUE Zhaorong, XIE Fei, WANG Xin, LI Hongyu. Effect of lienal polypeptide injection on primary immune thrombocytopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1229-1236.
[2]	LIN Zhong, XIE Qunli, DAI Shuping, CHEN Jing, LIN Feiyang, ZHU Yanwu, YU Guoliang, ZHANG Yuanhuai, CUI Ke. Population pharmacokinetics of Linezolid in Chinese adult infection patients#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 992-999.
[3]	. Research progress of linezolid-induced lactic acidosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1408-1413.
[4]	WU Haibing, ZHANG Gang, HAN Bin, GUO Xiaojun, JI Zhaoning. Clinical features and risk factors for infecfions in multiple myeloma during chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 93-98.
[5]	XU Jia, HUANG Qi, YANG Zhiling . Evaluation of clinical rationality of linezolid in our hospital in 2016 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 110-115.
[6]	LI Chun-xing, FU Qiang, ZHU Zhu. The tissue penetration and pharmacodynamics of linezolid in the infected tissues [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 349-355.
[7]	JIN Yan-jie, ZHANG Jing, LU Ke-peng, LIU Qian, LIN Li-min, SONG Hong-tao. Linezolid pharmacokinetics/pharmacodynamics and the development of dosage regimen design optimization [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1429-1434.
[8]	WEI Meng, TAO Yi-fu, YE Fei, XIE Du-jiang, ZHU Jun-rong, YU Feng. Investigation and analysis on initial warfarin dosage and hemorrhagic risk factors for atrial fibrillation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(1): 83-87.
[9]	LIANG Bei-bei, WANG Rui, BAI Nan, CAI Yun. Mutant prevention concentrations study of linezolid and vancomycin against methicillin-resistant staphylococcus aureus isolates [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(3): 251-254.
[10]	LIANG Bei-bei, WANG Rui. Study on in vitro antimicrobial activity of linezolid, vancomycin and other antibacterials against 111 methicillin resistant staphylococcus aureus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(9): 1044-1047.
[11]	XIAO Xiu-mei, LIU Zheng-ying, ZHANG Xiao-wei, ZHANG Jie. Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(9): 1048-1052.
[12]	YUAN Guo-long, XU Liang, LI Zhi, CHEN Lan-fang, XUAN Dan, LU Jin-ming. Effects of serum without immunoglobulin G from patients with systemic lupus erythematosus associated thrombocytopenia on megakaryocyto-poiesis of normal stem cells derived from cord blood [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(10): 1163-1167.
[13]	SU Ying-jie, LI Jing, YAO Ming-hui, GONG Qin-yan. Radioprotective effect of rhTPO on mice and MO7e cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(1): 66-71.
[14]	XU Guo-liang, XIAO Bing-hua, CHEN Qi, XU You-mei. Establishment of mouse model of Cytosine arabinoside-induced thrombocy-topenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(4): 387-390.